Opiant Pharmaceuticals (OPNT) Stock Rating Upgraded by ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Opiant Pharmaceuticals (NASDAQ:OPNT) from a sell rating to a hold rating in a research report released on Tuesday.

Separately, Cantor Fitzgerald reissued an overweight rating on shares of Opiant Pharmaceuticals in a research note on Thursday, June 14th.

NASDAQ:OPNT opened at $23.01 on Tuesday. The firm has a market cap of $64.41 million, a P/E ratio of 7.83 and a beta of -0.04. Opiant Pharmaceuticals has a 52-week low of $12.75 and a 52-week high of $51.90.

Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its quarterly earnings data on Thursday, August 9th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.55. The company had revenue of $3.15 million during the quarter, compared to analyst estimates of $2.10 million. Opiant Pharmaceuticals had a negative return on equity of 471.43% and a negative net margin of 449.52%. equities analysts expect that Opiant Pharmaceuticals will post -5.4 EPS for the current fiscal year.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Recommended Story: Penny Stocks, Risk and Reward Factors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply